This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum
April 28–29, 2026
Kerry Hotel Pudong, Shanghai, ChinaMay 6–7, 2026 - Digital Partnering
Book Now
Menu
Book Now

Tae Erk Kim
CEO at Crosspoint Therapeutics
Presenter

Profile

Description or SummaryDeveloping next gen ADC and immune agonistic anti cancer antibody therapies based on proprietary Fc silent platform technology. We have 1 lead stage immuno-oncology pipeline targeting CD47 and CD40 and 1 lead tage ADC pipeline targeting EGFR

At this event

Prev
Next
Wheeseong Lee
CEO/Founder
Lmito Therapeutics

See Tae Erk at ChinaBio® Partnering Forum

Book Now